Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2389 - Inflammatory indexes strongly predict clinical outcome in patients (pts) with metastatic renal cell cancer (mRCC) treated with nivolumab: results from the Italian Expanded Access Program (EAP)

Date

10 Sep 2017

Session

Poster display session

Presenters

Ugo De Giorgi

Citation

Annals of Oncology (2017) 28 (suppl_5): v295-v329. 10.1093/annonc/mdx371

Authors

U. De Giorgi1, G. Procopio2, A. Guida3, A. Bearz4, S. Buti5, U. Basso6, M. Mitterer7, C. Ortega8, P. Bidoli9, F. Ferrau10, L. Crinò11, A. Frassoldati12, P. Marchetti13, E. Mini14, A. Scoppola15, C. Verusio16, G. Fornarini17, G. Cartenì18, C. Caserta19, C.N. Sternberg20

Author affiliations

  • 1 Medical Oncology, Istituto Tumori della Romagna I.R.S.T., 47014 - Meldola/IT
  • 2 Medical Oncology, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 3 Medical Oncology, Azienda Ospedaliero - Universitaria Policlinico di Modena, 41100 - Modena/IT
  • 4 Medical Oncology, Cro, 33081 - Pordenone/IT
  • 5 Medical Oncology, Azienda Ospedaliera di Parma, 43126 - Parma/IT
  • 6 Medical Oncology, Istituto Oncologico Veneto IRCCS, 35128 - Padova/IT
  • 7 Medical Oncology, Ospedale Franz Tappeiner, Merano/IT
  • 8 Medical Oncology, IRCCS Istituto di Candiolo, 10060 - Candiolo/IT
  • 9 Medical Oncology Unit, San Gerardo Hospital, Monza (MI)/IT
  • 10 Medical Oncology, Ospedale San Vincenzo, 98039 - Taormina/IT
  • 11 Medical Oncology, Ospedale S. Maria della Misericordia, 06156 - Perugia/IT
  • 12 Medical Oncology, Azienda Ospedaliera di Ferrara St. Anna, 44100 - Ferrara/IT
  • 13 Medical Oncology, Azienda Ospedaliera St. Andrea, 00189 - Roma/IT
  • 14 Department Of Experimental And Clinical Medicine, University of Florence, Florence/IT
  • 15 Medical Oncology, Istituto Dermopatico dell’Immacolata, Roma, Roma/IT
  • 16 Medical Oncology, Ospedale di Saronno, 21047 - Saronno/IT
  • 17 Medical Oncology, Ospedale “S. Martino”, Genova/IT
  • 18 Medical Oncology, Azienda Ospedaliera di Rilievo Nazionale "Antonio Cardarelli"-AORN A. Cardarelli, 80131 - Napoli/IT
  • 19 Medical Oncology, Azienda Ospedaliera Sta Maria, 5100 - Terni/IT
  • 20 Department Of Oncology, San Camillo and Forlanini Hospitals, 156 - Roma/IT
More

Resources

Abstract 2389

Background

Biomarkers for outcome after immune-checkpoint blockade in mRCC are needed. We aimed to verify the prognostic impact of inflammatory indexes based on baseline values of neutrophils (N), lymphocytes (L) and/or platelets (P) in pts with mRCC included in the Italian nivolumab EAP.

Methods

Pts who had received ≥ 1 dose of nivolumab 3 mg/kg every 2 weeks in the Italian EAP after at least one prior systemic therapy for mRCC were enrolled in this study. The pre-treatment systemic immune-inflammation index (SII) defined as P×N/L, neutrophil-to-lymphocyte ratio (NLR) defined as N/L and platelet-to-lymphocyte ratio (PLR) defined as P/L were evaluated to identify a potential correlation with overall survival (OS). X-tile 3.6.1 software was used to identify cut-off values. OS was estimated by the Kaplan-Meier method and compared with the log-rank test. The impact of SII, NLR, and PLR on OS was evaluated by Cox regression analyses and on best overall response rate (ORR) by binary logistic regression.

Results

A total of 346 mRCC pts treated with nivolumab were included. SII ≥ 1375, NLR ≥ 3 and PLR ≥ 232 were considered as elevated levels (high risk groups). One-year OS in low and high SII group was 77% and 36%, respectively (p 

Conclusions

SII, NLR, and PLR are robust inflammatory prognostic factors for predicting outcome in mRCC pts treated with nivolumab. SII is a more powerful predictive system than the other inflammatory indexes for these pts.

Clinical trial identification

expanded access program

Legal entity responsible for the study

Italian RCC EAP Group

Funding

None

Disclosure

U. De Giorgi: advisory board Bristol-Myers Squib. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.